Evidence map›Paper›PMID 31380107›Full record

ArticleJournal of materials chemistry. B2018

A polymer-free, biomimicry drug self-delivery system fabricated via a synergistic combination of bottom-up and top-down approaches.

Xiaobao Xu, Gaomai Yang, Xiangdong Xue, Hongwei Lu, Hao Wu, Yee Huang, Di Jing, Wenwu Xiao, Jingkui Tian, Wei Yao and 3 more

Abstract read
In one paragraph

Article in Journal of materials chemistry. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Xiaobao Xu *College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 310027, China.
Gaomai Yang *Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Xiangdong XueDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Hongwei LuDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Hao WuDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Yee HuangInstitute of Animal Husbandry and Veterinary Science, Zhejiang Academy of Agricultural Sciences, Hangzhou, Zhejiang 310021, China.
Di JingDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Wenwu XiaoDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Jingkui TianCollege of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou 310027, China.
Wei YaoDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA.
Chong-Xian PanDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA.
Tzu-Yin LinDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
UC Davis Comprehensive Cancer CenterUniversity of California, Davis · USHangzhou Xixi hospital · CNAnimal Husbandry & Veterinary · IN

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Nano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated MalignanciesR01CA232845 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO, LI, YUANPEI · 2018 to 2022
$3.2M
Targeted-and timed-releasing nanotherapeutics against leukemia stem cellsR01CA176803 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PAN, CHONG-XIAN · 2015 to 2019
$1.8M
Stimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8M
Smart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumorsR01HD086195 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2016 to 2020
$1.6M
Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancerI01BX003840 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2018 to 2021
–
BLRD VA I01 BX001784BLRD VA I01 BX003840NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA176803NCI NIH HHS R01 CA199668NCI NIH HHS R01 CA232845NICHD NIH HHS R01 HD086195
6 · The paper itself

Abstract

Compared to conventional carrier-assistant drug delivery systems (DDSs), drug self-delivery systems (DSDSs) have advantages of unprecedented drug loading capacity, minimized carrier-related toxicity and ease of preparation. However, the colloidal stability and blood circulation time of DSDSs still need to be improved. Here we report on the development of a novel biomimicry drug self-delivery system by the integration of a top-down cell membrane complexing technique into our self-delivery multifunctional nano-platform made from bottom-up approach that contains 100% active pharmaceutical ingredients (API) of Pheophorbide A and Irinotecan conjugates (named PI). Compared to conventional cell membrane coated nanoparticles with polymer framework as core and relatively low drug loading, this system consisting of red blood cell membrane vesicles complexed PI (RBC-PI) is polymer-free with up to 50% API loading. RBC-PI exhibited 10 times higher area under curve in pharmacokinetic study and much lower macrophage uptake compared with the parent PI nanoparticles. RBC-PI retained the excellent chemophototherapeutic effects of the PI nanoparticles, but possessed superior anti-cancer efficacy with prolonged blood circulation, improved tumor delivery, and enhanced photothermal effects in animal models. This system represents a novel example of using cell membrane complexing technique for effective surface modification of DSDSs. This is also an innovative study to form a polymer-free cell membrane nanoparticle complexing with positive surface charged materials. This biomimicry DSDS takes advantages of the best features from both systems to make up for each other's shortcomings and posed all the critical features for an ideal drug delivery system.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorChlorophyllDrug CarriersDrug LiberationErythrocyte MembraneFemaleHumansIrinotecanLightMice, NudeNanoparticlesPhotochemotherapyPhotosensitizing AgentsRats, Sprague-DawleyAntineoplastic AgentsChlorophyllDrug CarriersIrinotecanpheophorbide aPhotosensitizing Agents

Identifiers

PMID31380107
PMCPMC6676892
OpenAlexW2901182329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.